Gilead Sciences, Inc. (NASDAQ:GILD) is scheduled to speak at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference on Monday, January 6. Speaking on behalf of the company will be Gilead Sciences Chairman and Chief Executive Officer John Martin, PhD. He will provide an overview of the company at 11:00 am ET that morning. Interested parties may listen to a live webcast of the event on the company’s website, www.gilead.com. Listeners are asked to log on fifteen minutes early to ensure a timely connection.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC’s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
